Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCHIX:CEVIS 94 Equity-to-Asset is 0.78 as of Jun. 2026, which is 1% above its 10-year median of 0.77. GuruFocus rates CHIX:CEVIS with a GF Score™ of 94/100 and a GF Value™ of kr218.16. The stock has 1 warning sign investors should review. Among 852 Medical Devices & Instruments companies, CellaVision AB ranks better than 72.3% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CellaVision AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr885.9 Mil. CellaVision AB's Total Assets for the quarter that ended in Jun. 2026 was kr1,142.2 Mil.
Therefore, CellaVision AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.78.
The historical rank and industry rank for CellaVision AB's Equity-to-Asset or its related term are showing as below:
CHIX:CEVIs'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.54 Med: 0.77 Max: 0.83
Current: 0.78
During the past 13 years, the highest Equity to Asset Ratio of CellaVision AB was 0.83. The lowest was 0.54. And the median was 0.77.
CHIX:CEVIs's Equity-to-Asset is ranked better than 72.3% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs CHIX:CEVIs: 0.78
CellaVision AB (CHIX:CEVIs) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CellaVision AB Equity-to-Asset Related Terms
CellaVision AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CEVIS vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, CellaVision AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CellaVision AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CHIX:CEVIS) has a Equity-to-Asset of 0.78 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CellaVision AB and its competitors. This is near median its historical median of 0.77. Over the past decade, CellaVision AB's Equity-to-Asset has ranged from 0.54 to 0.83. According to the industry distribution chart, CellaVision AB ranks #236 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 27.7%.
Is CellaVision AB's Equity-to-Asset too high?
CellaVision AB's current Equity-to-Asset of 0.78 is near median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 0.83. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. CellaVision AB's value of 0.78 is 20.9% above this industry median. Based on the distribution chart, CellaVision AB ranks #236 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #236 out of 852 companies for Equity-to-Asset. This puts CellaVision AB in the upper half of its industry. The industry median Equity-to-Asset is 0.65. CellaVision AB's value of 0.78 is 20.9% above this benchmark. Historically, CellaVision AB's own Equity-to-Asset has ranged from 0.54 to 0.83 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.65, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Equity-to-Asset of 0.78 is 20.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Equity-to-Asset is 0.78, which is near median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Equity-to-Asset of 0.78. The stock's GF Value™ is kr218.16, compared to a current price of kr160.20 — trading 26.6% below its estimated fair value. The current Equity-to-Asset is 0.78, which is near median its 10-year median of 0.77 and 20.9% above the Medical Devices & Instruments industry median of 0.65. CellaVision AB's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Equity-to-Asset is 0.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 26.6% below its estimated GF Value™ of kr218.16.
Key valuation signals for CHIX:CEVIS:
Equity-to-Asset: 0.78 (near median its 10-year median of 0.77)
GF Value™: kr218.16 vs. price of kr160.20 (26.6% below fair value)
Industry Position: 20.9% above the Medical Devices & Instruments median (#236 of 852)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
94GF Score
Get the complete analysis for CHIX:CEVIS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
